Journal Club: Dr Daniel Casey discusses CRISPR-Cas9

Posted on: Saturday 10 July 2021

For our next session of Journal Club we welcome guest host Dr Daniel Casey.

 

Daniel has chosen to review:

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

https://doi.org/10.1056/NEJMoa2107454

Gillmore, J. D. et al. (June 26 2021) “CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.” The New England Journal of Medicine. DOI: 10.1056/NEJMoa2107454

 

 

Dr Daniel Casey is a pharmaceutical physician currently working as Country Medical Lead for Celltrion Healthcare UK.

He is a Member of the Royal College of Psychiatrists and a Member of the Royal College of Physicians of London. He is currently an ST3 in the Pharmaceutical Medicine Specialty Training programme.

Dr Daniel Casey

FPM members only